Xeligekimab

DB18869InvestigationalProtein Based Therapies

Xeligekimab is under investigation in clinical trial NCT06028490 (A Study of Il4rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis.).

Mechanism: Pharmacologically active on Interleukin-17A
Curator reviewed
Also known as: Immunoglobulin g4 (235-proline), anti-(human interleukin 17a) (human monoclonal gr1501 .gamma.4-chain), disulfide with human monoclonal gr1501 .kappa.-chain, dimer

Resolves to

Compound

UNIIMC5WXU879ECAS2382921-73-3

Targets

Q16552IL17A

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Xeligekimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account